| Apr 1 |
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
|
| Mar 26 |
Gain Therapeutics GAAP EPS of -$1.71 misses by $0.14, revenue of $0.05M misses by $0.25M
|
| Mar 26 |
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
|
| Mar 15 |
Gain Therapeutics to Present at Public Ventures Discovery Day
|
| Mar 5 |
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
|
| Mar 5 |
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
|
| Feb 27 |
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
| Feb 14 |
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
|
| Feb 6 |
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
|
| Feb 6 |
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
|
